Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

This single-arm exploratory study plans to enroll 69 locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients. Participants will receive Adebrelimab (PD-L1 antibody) plus TP regimen (docetaxel/cisplatin) as neoadjuvant therapy for 1-4 weeks, followed by surgery and subsequent follow-up phase.

Trial Details

NCT ID
NCT07055841
Phase
PHASE2
Sponsor
Xiuping Ding
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Adebrelimab
  • TP regimen
  • Surgery or radiotherapy
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • 1\. Patients with head and neck squamous cell carcinoma diagnosed by histology or cytology;
  • 2\. Have not received systematic treatment for head and neck squamous cell carcinoma in the past;
  • 3\. According to the AJCC TNM staging system, it is divided into stages III-IVB;
  • 4\. ECOG score: 0-1 point;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →